Expertise in
11
conditions

Dr. Jonathan Rosenberg

Oncology
Sidney Kimmel Center For Prostate And Urologic Cancers
353 E 68th St, 
New York, NY 
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
Sidney Kimmel Center For Prostate And Urologic Cancers
353 E 68th St, 
New York, NY 

Overview

Jonathan Rosenberg is an Oncologist practicing medicine in New York, New York.

Dr. Rosenberg is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Nephrectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 283 peer reviewed articles and participating in 5 clinical trials. Dr. Rosenberg is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Sidney Kimmel Center for Prostate and Urologic Cancers
353 E 68th St, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules
Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules
Enrollment Status: Active_not_recruiting
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 2
Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Drug
Study Drug: BGJ398
Study Phase: Not Applicable
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
Pilot Study to Collect Blood From Research Subjects Allergic and Non-allergic to Peanut to Study Immune Modulation With Anti-IgE Therapy in Mice
Pilot Study to Collect Blood From Research Subjects Allergic and Non-allergic to Peanut to Study Immune Modulation With Anti-IgE Therapy in Mice
Enrollment Status: Completed
Publish Date: December 06, 2023
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Bevacizumab, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 3
View 4 Less Clinical Trials

283 Total Publications

Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102).
Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102).
Journal: JCO oncology advances
Published: June 03, 2026
Similar Doctors
Expertise in
33
conditions
Dr. Alison Moskowitz
Hematology | Oncology
Expertise in
33
conditions
Dr. Alison Moskowitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.1 miles away)
332-456-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Moskowitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Moskowitz is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moskowitz is currently accepting new patients.

Expertise in
26
conditions
Dr. Steven Horwitz
Hematology | Oncology
Expertise in
26
conditions
Dr. Steven Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.1 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles Salles
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.1 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Frequently Asked Questions about Dr. Jonathan Rosenberg

How do I make an appointment with Dr. Jonathan Rosenberg?

You can book an appointment with Dr. Jonathan Rosenberg by calling their office at 332-241-5848. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan Rosenberg a top-rated expert for Urothelial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan Rosenberg is classified as an Elite expert for Urothelial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan Rosenberg specialize in?

While Dr. Jonathan Rosenberg is a Oncology, they have specific expertise in Urothelial Cancer, Bladder Cancer, and Upper Tract Urothelial Carcinoma (UTUC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jonathan Rosenberg participate in research or clinical trials?

Yes. Dr. Jonathan Rosenberg has published 283 articles and abstracts on conditions like Urothelial Cancer. You can view a list of Dr. Jonathan Rosenberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan Rosenberg accept my insurance?

Dr. Jonathan Rosenberg accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 332-241-5848 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenberg's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile